These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 31179899)

  • 1. Implications of
    Carson P; Cade A
    Pharm Pat Anal; 2019 May; 8(3):65-70. PubMed ID: 31179899
    [No Abstract]   [Full Text] [Related]  

  • 2. How Cuozzo will impact the interplay between post grant proceedings and Hatch-Waxman litigation.
    Mishra N; Doody PA; Davé RS
    Pharm Pat Anal; 2017 Jan; 6(1):9-15. PubMed ID: 28181455
    [No Abstract]   [Full Text] [Related]  

  • 3. Inter Partes Review: Patent Killer No More?
    Chen FC; Lee PS
    Trends Biotechnol; 2019 Jul; 37(7):680-683. PubMed ID: 30890272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Obviousness, hindsight and perspective: the impact of KSR v. Teleflex on biotech and pharmaceutical patents.
    Teitelbaum R; Cohen M
    Nat Biotechnol; 2007 Oct; 25(10):1105-6. PubMed ID: 17921990
    [No Abstract]   [Full Text] [Related]  

  • 5. Muddying the waters: how the Supreme Court's decision in Merck v. Integra fails to resolve problems of judicial interpretation of 35 U.S.C. Section 271(E)(1), the "safe harbor" provision of the Hatch-Waxman Act.
    Sertic M
    Health Matrix Clevel; 2007; 17(2):377-439. PubMed ID: 18326397
    [No Abstract]   [Full Text] [Related]  

  • 6. The Generic Drug Industry Embraces a Faster, Cheaper Pathway for Challenging Patents.
    Darrow JJ; Beall RF; Kesselheim AS
    Appl Health Econ Health Policy; 2019 Feb; 17(1):47-54. PubMed ID: 30141133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Supreme Court boosts licensees in biotech patent battles.
    Waltz E
    Nat Biotechnol; 2007 Mar; 25(3):264-5. PubMed ID: 17344866
    [No Abstract]   [Full Text] [Related]  

  • 8. Biotech patents: looking backward while moving forward.
    Eisenberg RS
    Nat Biotechnol; 2006 Mar; 24(3):317-9. PubMed ID: 16525404
    [No Abstract]   [Full Text] [Related]  

  • 9. An Administrative Meter Maid: Using Inter Partes Review and Post-Grant Review to Curb Exclusivity Parking via the "Failure to Market" Provision of the Hatch-Waxman Act.
    Apel BT
    Mich Law Rev; 2015; 114(1):107-36. PubMed ID: 26394458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strange Bedfellows: Native American Tribes, Big Pharma, and the Legitimacy of Their Alliance.
    Kennedy DC
    Duke Law J; 2019 Apr; 68(7):1433-68. PubMed ID: 30995705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The biotechnology industry organization's view on Hatch-Waxman reform.
    Schmickel D
    Food Drug Law J; 1999; 54(2):241-2. PubMed ID: 11758580
    [No Abstract]   [Full Text] [Related]  

  • 12. Intellectual property. Biotech feels a chill from changing U.S. patent rules.
    Servick K
    Science; 2014 Jul; 345(6192):14-5. PubMed ID: 24994626
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmaceutical patent life-cycle management after KSR v. Teleflex.
    Furrow ME
    Food Drug Law J; 2008; 63(1):275-320. PubMed ID: 18561462
    [No Abstract]   [Full Text] [Related]  

  • 14. US Supreme Court applies strict limits to patents.
    Robertson D
    Nat Biotechnol; 2002 Jul; 20(7):639. PubMed ID: 12089532
    [No Abstract]   [Full Text] [Related]  

  • 15. Patents. U.S. Supreme Court delves into what is and isn't patentable.
    Marshall E
    Science; 2009 Jun; 324(5933):1374. PubMed ID: 19520926
    [No Abstract]   [Full Text] [Related]  

  • 16. Sequenom, the U.S. Supreme Court, and Personalized Medicine.
    Kodroff CA
    Hum Gene Ther Clin Dev; 2016 Jun; 27(2):49-52. PubMed ID: 27267566
    [No Abstract]   [Full Text] [Related]  

  • 17. Hatch-Waxman in the Federal Courts: from 1994--2004.
    Ludwig SP; Kosinski KB; Harris J
    Drug Dev Ind Pharm; 2005 Jan; 31(2):215-22. PubMed ID: 15773288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Judicial developments in the US Hatch-Waxman infringement safe harbor.
    Swirnoff AH; Becker DM
    Expert Opin Ther Pat; 2010 Apr; 20(4):451-8. PubMed ID: 20302449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hatch-waxman changes debated.
    Chahine K
    Nat Biotechnol; 2000 Jul; 18(7):710-1. PubMed ID: 10888831
    [No Abstract]   [Full Text] [Related]  

  • 20. Antibody-patent row could have far-reaching impact on biotech.
    Ledford H
    Nature; 2023 Apr; 616(7955):17. PubMed ID: 36977755
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.